Evaluation of carbopol as an adjuvant on the effectiveness of progressive atrophic rhinitis vaccine

Zhang, Jiansong; Wang, Meifen; Zhou, Ni-Ni; Shen, Yijuan; Li, Yufeng

doi:10.1016/j.vaccine.2018.06.023

Cited by 11 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the innate immunity profile of SPA09 in the MIMIC® PTE module has some differences when compared to AddaVax™, a commercial MF59-like benchmark adjuvant, this profile was in accordance with in vivo observations in animal models. Taken together, these data confirm the value of SPA09 as a potential human vaccine adjuvant candidate based on a low inflammatory profile with innate immune activation, which could lead to T cell responses and antibody secretion as reported for other adjuvants with similar composition ( Zhang et al, 2018 ).…”

Section: Discussionsupporting

confidence: 84%

“…Among the adjuvant-active PAAs, one can find plain PAAs ( Diamantstein et al, 1971 ; Hilgers et al, 1998a ), PAA dendrimers ( Zaman et al, 2010 , 2011 ), PAA alkyl esters ( Hilgers et al, 2000 , 1998b ; Tifrea et al, 2011 ) and the crosslinked PAAs ( i.e. Carbomers™ and Carbopols™) that are present in various experimental and commercial veterinary vaccines ( Angelos et al, 2016 ; Deville et al, 2011 , 2008 ; Gelfi et al, 2010 ; Gualandi et al, 1988 ; Hoogland et al, 2006 ; Kim et al, 2012 ; Liu et al, 2005 ; Mair et al, 2015 ; Minke et al, 2006 ; Mumford et al, 1994 ; Tollersrud et al, 2002 ; Zhang et al, 2018 ). Potent adjuvant systems were also obtained by combining Carbopol™ with oil-in-water emulsions ( Dey et al, 2012 ; Lai et al, 2012 ; Sastry et al, 2017 ) or by co-formulating Carbomer™ with lecithin in an adjuvant system termed Adjuplex™ (Advanced BioAjuvants LLC) ( Chakrabarti et al, 2013 ; Gasper et al, 2016 ; Sastry et al, 2017 ; Wegmann et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A potent novel vaccine adjuvant based on straight polyacrylate

Garinot

Piras-Douce

Probeck

et al. 2020

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

A structure-activity study was conducted to identify the structural characteristics underlying the adjuvant activity of straight ( i.e. non-crosslinked) polyacrylate polymers (PAAs) in order to select a new PAA adjuvant candidate for future clinical development. The study revealed that the adjuvant effect of PAA was mainly influenced by polymer size (Mw) and dose. Maximal effects were obtained with large PAAs above 350 kDa and doses above 100 μg in mice. Small PAAs below 10 kDa had virtually no adjuvant effect. HPSEC analysis revealed that PAA polydispersity index and ramification had less impact on adjuvanticity. Heat stability studies indicated that residual persulfate could be detrimental to PAA stability. Hence, this impurity was systematically eliminated by diafiltration along with small Mw PAAs and residual acrylic acid that could potentially affect product safety, potency and stability. The selected PAA, termed SPA09, displayed an adjuvant effect that was superior to that of a standard emulsion adjuvant when tested with CMV-gB in mice, even in the absence of binding to the antigen. The induced immune response was dominated by strong IFNγ, IgG2c and virus neutralizing titers. The activity of SPA09 was then confirmed on human cells via the innate immune module of the human MIMIC® system.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

A potent novel vaccine adjuvant based on straight polyacrylate

Garinot

Piras-Douce

Probeck

et al. 2020

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

show abstract

“…We compared the immunogenicities of CAV-2 vaccines featuring adjuvants developed by SEPPIC (France) and Lubrizol (USA). The Cabopol-adjuvanted vaccine afforded slightly higher specific IgG antibody and VNA titers in guinea pigs, as was also the case for the PRRS MLV and atrophic rhinitis vaccines; Cabopol induces rapid differentiation of IFN-r-producing cells (NK and CD4 + T cells) and also drives T cell differentiation [13,21]. The Korean veterinary standard states that a CAV vaccine should induce a VNA titer of at least 120 in dogs.…”

Section: Discussionmentioning

confidence: 77%

“…We passaged APQP1701 in MDCK cells in medium containing 5 mM urea, triggering mutations including the APQA1701-40P six-amino deletion in E1b-19K; this mutation may critically distinguish parent or field CAV-2 strains from the mutant; the mutation is a 'mark-er' of the vaccine. Both Cabopol and the IMS gel are safe and effective adjuvants [13,14,21]. Selection of an optimal adjuvant is essential when seeking to enhance the immune response to vaccination.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of a new, inactivated canine adenovirus type 2 vaccine for dogs

Yang

Kim

Yoo

et al. 2020

Clin Exp Vaccine Res

View full text Add to dashboard Cite

We constructed a new canine adenovirus type 2 (CAV-2) vaccine candidate using the recently isolated Korean CAV-2 strain; we termed the vaccine APQA1701-40P and evaluated its safety and immunogenicity in dogs. Materials and Methods: To generate the anti-CAV-2 vaccine, APQA1701 was passaged 40 times in MDCK cells growing in medium containing 5 mM urea and the virus was inactivated using 0.05% (volume per volume) formaldehyde. Two vaccines were prepared by blending inactivated APQA1701-40P with two different adjuvants; both were intramuscularly injected (twice) into guinea pigs. The safety and immunogenicity of the Cabopol-adjuvanted vaccine were evaluated in seronegative dogs. The humoral responses elicited were measured using an indirect enzyme-linked immunosorbent assay (I-ELISA), and via a virus neutralization assay (VNA). Results: The new, inactivated CAV-2 vaccine strain, APQA1701-40P, lacked six amino acids of the E1b-19K protein. In guinea pigs, the Cabopol-adjuvanted vaccine afforded a slightly higher VNA titer and I-ELISA absorbance than an IMS gel-adjuvanted vaccine 4 weeks postvaccination (p>0.05). Dogs inoculated with the former vaccine developed a significantly higher immune titer than non-vaccinated dogs. Conclusion: The Cabopol-adjuvanted, inactivated CAV-2 vaccine was safe and induced a high VNA titer in dogs.

show abstract

“…Samples were cultured on brain-heart infusion agar (Difco Labora-D. Quintanar-Guerrero et al tories, Detroit, MI, USA) and incubated aerobically overnight at 37˚C. Pasteurella multocida type A was identified by standard procedures [15] [16]. The biomass was inactive with formaldehyde 0.5% for 12 hours by washing the plates with PBS, and the bacterial concentration was standardized spectrophotometrically (660 nm) at 10 8 CFU/ml.…”

Section: Bacterial Strainmentioning

confidence: 99%

Evaluation Preliminary of a Dry Emulsion System as a <i>Pasteurella multocida</i> Oral Carrier for Pigs

Quintanar‐Guerrero¹,

Ceron²,

Ortega³

et al. 2020

JBM

View full text Add to dashboard Cite

Background: This work evaluated the capacity of a dry emulsion as a carrier of viable microorganisms with potential use as prophylaxis of infectious diseases. Methods: The aqueous phase containing P. multocida not viable in PBS was emulsified in mineral oil to obtain a w/o emulsion. The microorganisms remained stable and only in two cases (n = 6) did the bacterial concentration decrease. Scanning Electron Microscopy (SEM) revealed a structure of a system with the organized association of particles with cubic symmetry. Using two ex vivo bioadhesion systems, it was demonstrated that the disperse-adsorbed system is capable of adhering to the intestinal mucosa and remains adhered for long periods of time. Results: The no viability of the bacteria in the dry emulsion and the possibility of controlled release were confirmed. In vivo trial was conducted in pigs. It was possible to locate the emulsion and the bacteria attached to the gut of the living animal. An ELISA kit was used to monitor the mean antibody titer of treated pigs over a 2-week period, and a classic primary response curve occurred when the titer was plotted against time. Conclusion: We propose the disperse-adsorbed system as an alternative to commonly used vehicles for immunogens in the oral vaccines.

show abstract

Evaluation of carbopol as an adjuvant on the effectiveness of progressive atrophic rhinitis vaccine

Cited by 11 publications

References 28 publications

A potent novel vaccine adjuvant based on straight polyacrylate

A potent novel vaccine adjuvant based on straight polyacrylate

Immunogenicity of a new, inactivated canine adenovirus type 2 vaccine for dogs

Evaluation Preliminary of a Dry Emulsion System as a <i>Pasteurella multocida</i> Oral Carrier for Pigs

Contact Info

Product

Resources

About

Evaluation of carbopol as an adjuvant on the effectiveness of progressive atrophic rhinitis vaccine

Cited by 11 publications

References 28 publications

A potent novel vaccine adjuvant based on straight polyacrylate

A potent novel vaccine adjuvant based on straight polyacrylate

Immunogenicity of a new, inactivated canine adenovirus type 2 vaccine for dogs

Evaluation Preliminary of a Dry Emulsion System as a &lt;i&gt;Pasteurella multocida&lt;/i&gt; Oral Carrier for Pigs

Contact Info

Product

Resources

About

Evaluation Preliminary of a Dry Emulsion System as a <i>Pasteurella multocida</i> Oral Carrier for Pigs